Instructions for Heparin-Darnitsa gel 600 units/g tube 30 g
Composition
active ingredient: heparin;
1 g of gel contains 600 IU of heparin sodium;
Excipients: carbomer, tromethamine, propylene glycol, benzyl alcohol, purified water.
Dosage form
Gel.
Main physicochemical properties: homogeneous, transparent, colorless gel, with a faint specific odor.
Pharmacotherapeutic group
Means for use in varicose veins. Heparin. ATC code C05B A03.
Pharmacological properties
Pharmacodynamics
Heparin sodium is a direct-acting anticoagulant; it blocks the biosynthesis of thrombin, inhibits the formation of fibrin from fibrinogen, reduces platelet aggregation and inhibits the activity of hyaluronidase. When applied topically, Heparin-Darnitsa gel has antithrombotic, anti-inflammatory and anti-edematous effects. The drug does not exhibit local irritant effects.
Pharmacokinetics
When applied to the skin, a small amount of heparin sodium enters the systemic bloodstream, which is excreted mainly by the kidneys.
Indication
Treatment of superficial vein diseases such as varicose veins and related complications, phlebothrombosis, thrombophlebitis, superficial periphlebitis. Postoperative varicose phlebitis, complications after surgical removal of the saphenous vein of the leg. Injuries and bruises, infiltrates and localized edema, subcutaneous hematomas. Injuries and sprains of muscle-tendon and capsulo-ligamentous structures.
Contraindication
Individual hypersensitivity to heparin or any of the components of the drug, bleeding trophic leg ulcers and/or infected wounds, hemorrhagic diathesis, purpura, thrombocytopenia, hemophilia, tendency to bleeding.
Interaction with other medicinal products and other types of interactions
Oral anticoagulants - simultaneous use with Heparin-Darnitsa gel may cause prolongation of prothrombin time.
Nonsteroidal anti-inflammatory drugs, venotonic drugs - when used simultaneously, the effect of Heparin-Darnitsa gel is enhanced.
Medicines for external use (for example, nonsteroidal anti-inflammatory drugs) - when used simultaneously with Heparin-Darnitsa gel, the absorption of other medicines through the skin is significantly increased.
The drug should not be used together with topical medications, for example, with drugs containing tetracycline, hydrocortisone, salicylic acid, or anticoagulants.
Application features
Heparin-Darnitsa gel should not be applied to open wounds and should not be used in the presence of purulent processes.
Do not apply to large areas of skin, to areas of skin with increased sensitivity, or to mucous membranes. Do not allow the gel to get into the eyes.
It is recommended to monitor blood clotting parameters under the supervision of a doctor.
In case of blood clotting disorders, the gel is not recommended to be applied to large areas of the skin. The drug should not be prescribed for bleeding.
The drug should be used with caution in hemorrhagic processes.
In the case of treatment of phlebitis, the drug should not be rubbed into the skin.
Use during pregnancy or breastfeeding
Do not use the drug during pregnancy or breastfeeding.
Ability to influence reaction speed when driving vehicles or other mechanisms
Does not affect.
Method of administration and doses
The drug Heparin-Darnitsa is applied topically, 3-10 cm of gel is applied with light rubbing movements to the skin of the affected area 1-3 times a day. The dose of the drug depends on the area of the affected area.
The duration of treatment is determined by the doctor individually, taking into account the severity of the disease.
Children
Due to limited experience, the drug should not be prescribed to children.
Overdose
With topical application - unlikely. Due to the lack of information on accidental overdose or ingestion of the drug, there are no specific recommendations for these conditions.
Treatment: General supportive measures may be used.
Accidental oral administration of the gel may cause nausea or vomiting in a child. In this case, gastric lavage should be performed and, if necessary, symptomatic therapy should be administered. The effect of heparin can be neutralized with protamine sulfate.
Adverse reactions
Dermatological disorders: skin swelling, skin rash, itching, redness, swelling, burning sensation, hemorrhages, sometimes the appearance of small pustules, blisters or blisters, which quickly disappear after discontinuation of the drug.
Immune system disorders: hypersensitivity reactions, including urticaria, angioedema.
When applied to large areas of skin, systemic adverse reactions may develop.
Expiration date
3 years.
Storage conditions
Store in original packaging at a temperature not exceeding 15 °C.
Keep out of reach of children.
Packaging
30 g in a tube; 1 tube in a pack.
Vacation category
Without a prescription.
Producer
PrJSC "Pharmaceutical Company "Darnitsa".
Location of the manufacturer and its business address
Ukraine, 02093, Kyiv, Boryspilska St., 13.
